midazolam has been researched along with Diabetic Nephropathies in 2 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam is an anesthetic widely used for anxiolysis and sedation; however, to date, a possible role for midazolam in diabetic kidney disease remains unknown." | 5.72 | Midazolam Ameliorates Hyperglycemia-Induced Glomerular Endothelial Dysfunction by Inhibiting Transglutaminase 2 in Diabetes. ( Cho, S; Ha, KS; Hong, SH; Jeon, HY; Kim, EB; Kim, M; Lee, YJ; Sayyed, ND; Seo, JA, 2022) |
| "Midazolam is an anesthetic widely used for anxiolysis and sedation; however, to date, a possible role for midazolam in diabetic kidney disease remains unknown." | 1.72 | Midazolam Ameliorates Hyperglycemia-Induced Glomerular Endothelial Dysfunction by Inhibiting Transglutaminase 2 in Diabetes. ( Cho, S; Ha, KS; Hong, SH; Jeon, HY; Kim, EB; Kim, M; Lee, YJ; Sayyed, ND; Seo, JA, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seo, JA | 1 |
| Sayyed, ND | 1 |
| Lee, YJ | 1 |
| Jeon, HY | 1 |
| Kim, EB | 1 |
| Hong, SH | 1 |
| Cho, S | 1 |
| Kim, M | 1 |
| Ha, KS | 1 |
| Lluch Fernández, M | 1 |
| Vallejo Uclés, A | 1 |
| Vallejo Cantarero, F | 1 |
| Zurita Castro, F | 1 |
| Huelva Ramírez, E | 1 |
| Moreno Carmona, C | 1 |
2 other studies available for midazolam and Diabetic Nephropathies
| Article | Year |
|---|---|
Midazolam Ameliorates Hyperglycemia-Induced Glomerular Endothelial Dysfunction by Inhibiting Transglutaminase 2 in Diabetes.
Topics: Animals; Biomarkers; Calcium; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Neph | 2022 |
[Anesthesia and intraoperative treatment in 2 cases of simultaneous liver, pancreas, and kidney transplantation].
Topics: Adult; Anesthesia, General; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type 1; Diabetic Nephro | 1999 |